CHD1 and neoplasm: A major insight from our characterization of how CHD1 loss promotes enzalutamide resistance is the role of an altered chromatin landscape in establishing a cell state that enables more rapid adaptation to environmental stresses, such as antiandrogen therapy than can occur in CHD1-intact tumor cells.